Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,305.36 -2.77 (-0.05%) Dow
39,823.45 +16.68 (+0.04%) Nasdaq
16,752.47 -42.41 (-0.25%) Bitcoin USD
71,120.35 +4,293.56 (+6.42%) CMC Crypto 200
1,536.29 +47.75 (+3.21%)
Halozyme Therapeutics, Inc. (HALO)
- PR Newswire
Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous formulation of Opdivo® (nivolumab) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy mainten
- Zacks
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
- Zacks
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
